[SCHEDULE 13G] GameSquare Holdings, Inc. SEC Filing
On 07/15/2025, CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. jointly filed a Schedule 13G reporting a passive ownership of 1,000,000 BriaCell Therapeutics Corp. common shares (CUSIP 107930208). The stake equals 5.7 % of the 17.55 M shares outstanding, as cited in BriaCell鈥檚 July 2025 prospectus. Each Reporting Person claims 0 sole and 1,000,000 shared voting and dispositive power. Both entities disclaim beneficial ownership beyond their pecuniary interest and certify the shares were not acquired to influence control. Signatory: Sarah Travis (Heights Capital) on 07/22/2025. No group arrangements, subsidiaries, or additional controlling interests are disclosed.
Il 15/07/2025, CVI Investments, Inc. e il suo gestore degli investimenti Heights Capital Management, Inc. hanno presentato congiuntamente un Schedule 13G, segnalando una partecipazione passiva di 1.000.000 di azioni ordinarie di BriaCell Therapeutics Corp. (CUSIP 107930208). La quota rappresenta il 5,7% delle 17,55 milioni di azioni in circolazione, come indicato nel prospetto di BriaCell di luglio 2025. Ciascuna delle persone segnalanti dichiara di detenere 0 poteri di voto e disposizione esclusivi e 1.000.000 poteri condivisi. Entrambe le entit脿 negano la titolarit脿 effettiva oltre al loro interesse pecuniario e certificano che le azioni non sono state acquisite con l鈥檌ntento di influenzare il controllo. Firmataria: Sarah Travis (Heights Capital) il 22/07/2025. Non sono stati dichiarati accordi di gruppo, controllate o ulteriori interessi di controllo.
El 15/07/2025, CVI Investments, Inc. y su gestor de inversiones Heights Capital Management, Inc. presentaron conjuntamente un Schedule 13G reportando una participaci贸n pasiva de 1.000.000 de acciones comunes de BriaCell Therapeutics Corp. (CUSIP 107930208). La participaci贸n equivale al 5,7 % de las 17,55 millones de acciones en circulaci贸n, seg煤n el prospecto de BriaCell de julio de 2025. Cada persona informante declara tener 0 poderes exclusivos y 1.000.000 compartidos de voto y disposici贸n. Ambas entidades niegan la propiedad beneficiaria m谩s all谩 de su inter茅s pecuniario y certifican que las acciones no se adquirieron para influir en el control. Firmante: Sarah Travis (Heights Capital) el 22/07/2025. No se divulgan acuerdos de grupo, subsidiarias ni intereses de control adicionales.
2025雲� 7鞗� 15鞚�, CVI Investments, Inc.鞕赌 攴� 韴瀽 甏�毽瀽 Heights Capital Management, Inc.臧� 瓿惦彊鞙茧 Schedule 13G毳� 鞝滌稖頃橃棳 BriaCell Therapeutics Corp. 氤错喌欤� 1,000,000欤检棎 雽�頃� 靾橂彊鞝� 靻岇湢甓�(CUSIP 107930208)鞚� 氤搓碃頄堨姷雼堧嫟. 鞚� 歆�攵勳潃 BriaCell鞚� 2025雲� 7鞗� 鞎堧偞靹滌棎 氇呾嫓霅� 氚滍枆 欤检嫕 1,755毵� 欤检潣 5.7%鞐� 頃措嫻頃╇媹雼�. 臧� 氤搓碃鞛愲姅 雼弲 鞚橁舶甓� 0欤�鞕赌 瓿惦彊 鞚橁舶甓� 1,000,000欤�毳� 氤挫湢頃滊嫟瓿� 欤检灔頃╇媹雼�. 霊� 旮瓣磤 氇憪 瓴届牅鞝� 鞚挫澋鞚� 雱橃柎靹� 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙晿氅�, 欤检嫕鞚� 瓴届榿甓岇棎 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃╇媹雼�. 靹滊獏鞛�: Sarah Travis (Heights Capital), 2025雲� 7鞗� 22鞚�. 攴鸽９ 順戩暯, 鞛愴殞靷� 霕愲姅 於旉皜 歆�氚瓣秾鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.
Le 15/07/2025, CVI Investments, Inc. et son gestionnaire d鈥檌nvestissement Heights Capital Management, Inc. ont conjointement d茅pos茅 un Schedule 13G d茅clarant une possession passive de 1 000 000 d鈥檃ctions ordinaires de BriaCell Therapeutics Corp. (CUSIP 107930208). Cette participation repr茅sente 5,7 % des 17,55 millions d鈥檃ctions en circulation, selon le prospectus de BriaCell de juillet 2025. Chaque personne d茅clarante affirme d茅tenir 0 pouvoir de vote exclusif et 1 000 000 de pouvoirs partag茅s de vote et de disposition. Les deux entit茅s d茅clinent toute propri茅t茅 b茅n茅ficiaire au-del脿 de leur int茅r锚t p茅cuniaire et certifient que les actions n鈥檕nt pas 茅t茅 acquises pour influencer le contr么le. Signataire : Sarah Travis (Heights Capital) le 22/07/2025. Aucun accord de groupe, filiale ou int茅r锚t de contr么le suppl茅mentaire n鈥檈st divulgu茅.
Am 15.07.2025 reichten CVI Investments, Inc. und ihr Investmentmanager Heights Capital Management, Inc. gemeinsam ein Schedule 13G ein und meldeten einen passiven Besitz von 1.000.000 Stammaktien der BriaCell Therapeutics Corp. (CUSIP 107930208). Der Anteil entspricht 5,7 % der 17,55 Mio. ausstehenden Aktien, wie im Juli 2025 ver枚ffentlichten Prospekt von BriaCell angegeben. Jede meldende Person beansprucht 0 alleinige und 1.000.000 gemeinsame Stimm- und Verf眉gungsrechte. Beide Parteien lehnen eine wirtschaftliche Eigent眉merschaft 眉ber ihr finanzielles Interesse hinaus ab und best盲tigen, dass die Aktien nicht zum Zweck der Kontrolle erworben wurden. Unterzeichnerin: Sarah Travis (Heights Capital) am 22.07.2025. Es werden keine Gruppenvereinbarungen, Tochtergesellschaften oder weitere Kontrollinteressen offengelegt.
- None.
- None.
Insights
TL;DR: 5.7 % passive stake disclosed; institutional holder presence is neutral-to-slightly positive, no control intentions stated.
The filing introduces CVI/Heights Capital as a mid-sized shareholder, now above the 5 % reporting threshold. Shared, not sole, authority implies a coordinated but non-controlling position. Because the investment is certified as passive, no immediate strategic shift or activist pressure should be expected. From a liquidity perspective, 1 M shares represent modest ownership relative to BriaCell鈥檚 float, signalling limited market impact. Overall, disclosure enhances transparency but is not materially transformational.
TL;DR: Disclosure improves ownership clarity; passive stance lowers governance risk鈥攐verall neutral governance impact.
Schedule 13G confirms the investors鈥� passive status under Rule 13d-1(c), alleviating concerns of an unsolicited takeover attempt. Shared voting/dispositive power is typical for an investment manager structure and aligns with SEC requirements. The disclaimer of beneficial ownership beyond pecuniary interest further limits potential governance influence. No group formation, subsidiary involvement, or control-seeking language appears, suggesting standard institutional investment behaviour.
Il 15/07/2025, CVI Investments, Inc. e il suo gestore degli investimenti Heights Capital Management, Inc. hanno presentato congiuntamente un Schedule 13G, segnalando una partecipazione passiva di 1.000.000 di azioni ordinarie di BriaCell Therapeutics Corp. (CUSIP 107930208). La quota rappresenta il 5,7% delle 17,55 milioni di azioni in circolazione, come indicato nel prospetto di BriaCell di luglio 2025. Ciascuna delle persone segnalanti dichiara di detenere 0 poteri di voto e disposizione esclusivi e 1.000.000 poteri condivisi. Entrambe le entit脿 negano la titolarit脿 effettiva oltre al loro interesse pecuniario e certificano che le azioni non sono state acquisite con l鈥檌ntento di influenzare il controllo. Firmataria: Sarah Travis (Heights Capital) il 22/07/2025. Non sono stati dichiarati accordi di gruppo, controllate o ulteriori interessi di controllo.
El 15/07/2025, CVI Investments, Inc. y su gestor de inversiones Heights Capital Management, Inc. presentaron conjuntamente un Schedule 13G reportando una participaci贸n pasiva de 1.000.000 de acciones comunes de BriaCell Therapeutics Corp. (CUSIP 107930208). La participaci贸n equivale al 5,7 % de las 17,55 millones de acciones en circulaci贸n, seg煤n el prospecto de BriaCell de julio de 2025. Cada persona informante declara tener 0 poderes exclusivos y 1.000.000 compartidos de voto y disposici贸n. Ambas entidades niegan la propiedad beneficiaria m谩s all谩 de su inter茅s pecuniario y certifican que las acciones no se adquirieron para influir en el control. Firmante: Sarah Travis (Heights Capital) el 22/07/2025. No se divulgan acuerdos de grupo, subsidiarias ni intereses de control adicionales.
2025雲� 7鞗� 15鞚�, CVI Investments, Inc.鞕赌 攴� 韴瀽 甏�毽瀽 Heights Capital Management, Inc.臧� 瓿惦彊鞙茧 Schedule 13G毳� 鞝滌稖頃橃棳 BriaCell Therapeutics Corp. 氤错喌欤� 1,000,000欤检棎 雽�頃� 靾橂彊鞝� 靻岇湢甓�(CUSIP 107930208)鞚� 氤搓碃頄堨姷雼堧嫟. 鞚� 歆�攵勳潃 BriaCell鞚� 2025雲� 7鞗� 鞎堧偞靹滌棎 氇呾嫓霅� 氚滍枆 欤检嫕 1,755毵� 欤检潣 5.7%鞐� 頃措嫻頃╇媹雼�. 臧� 氤搓碃鞛愲姅 雼弲 鞚橁舶甓� 0欤�鞕赌 瓿惦彊 鞚橁舶甓� 1,000,000欤�毳� 氤挫湢頃滊嫟瓿� 欤检灔頃╇媹雼�. 霊� 旮瓣磤 氇憪 瓴届牅鞝� 鞚挫澋鞚� 雱橃柎靹� 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙晿氅�, 欤检嫕鞚� 瓴届榿甓岇棎 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃╇媹雼�. 靹滊獏鞛�: Sarah Travis (Heights Capital), 2025雲� 7鞗� 22鞚�. 攴鸽９ 順戩暯, 鞛愴殞靷� 霕愲姅 於旉皜 歆�氚瓣秾鞚� 瓿店皽霅橃 鞎婌晿鞀惦媹雼�.
Le 15/07/2025, CVI Investments, Inc. et son gestionnaire d鈥檌nvestissement Heights Capital Management, Inc. ont conjointement d茅pos茅 un Schedule 13G d茅clarant une possession passive de 1 000 000 d鈥檃ctions ordinaires de BriaCell Therapeutics Corp. (CUSIP 107930208). Cette participation repr茅sente 5,7 % des 17,55 millions d鈥檃ctions en circulation, selon le prospectus de BriaCell de juillet 2025. Chaque personne d茅clarante affirme d茅tenir 0 pouvoir de vote exclusif et 1 000 000 de pouvoirs partag茅s de vote et de disposition. Les deux entit茅s d茅clinent toute propri茅t茅 b茅n茅ficiaire au-del脿 de leur int茅r锚t p茅cuniaire et certifient que les actions n鈥檕nt pas 茅t茅 acquises pour influencer le contr么le. Signataire : Sarah Travis (Heights Capital) le 22/07/2025. Aucun accord de groupe, filiale ou int茅r锚t de contr么le suppl茅mentaire n鈥檈st divulgu茅.
Am 15.07.2025 reichten CVI Investments, Inc. und ihr Investmentmanager Heights Capital Management, Inc. gemeinsam ein Schedule 13G ein und meldeten einen passiven Besitz von 1.000.000 Stammaktien der BriaCell Therapeutics Corp. (CUSIP 107930208). Der Anteil entspricht 5,7 % der 17,55 Mio. ausstehenden Aktien, wie im Juli 2025 ver枚ffentlichten Prospekt von BriaCell angegeben. Jede meldende Person beansprucht 0 alleinige und 1.000.000 gemeinsame Stimm- und Verf眉gungsrechte. Beide Parteien lehnen eine wirtschaftliche Eigent眉merschaft 眉ber ihr finanzielles Interesse hinaus ab und best盲tigen, dass die Aktien nicht zum Zweck der Kontrolle erworben wurden. Unterzeichnerin: Sarah Travis (Heights Capital) am 22.07.2025. Es werden keine Gruppenvereinbarungen, Tochtergesellschaften oder weitere Kontrollinteressen offengelegt.
FAQ
How many BriaCell (BCTXZ) shares do CVI Investments and Heights Capital own?
What percentage of BriaCell鈥檚 outstanding shares does the 1 M-share position represent?
Is the CVI/Heights Capital position passive or activist?
Do CVI Investments or Heights Capital hold sole voting power over the shares?
When was the event triggering the Schedule 13G filing?
